This recommendation is of high relevance as the combined use of TKIs with SMO-GLI-1 inhibitors is currently being projected to be a high efficiency scheme that could reduce EMT tumor mechanisms in high-grade malignancies with poor prognosis, suggesting new therapeutic strategies for treating progressive lung cancer [129]. The gene discussed is SMO; the disease is lung cancer.